Ann: AD-214 effective in gold standard pre-clinical animal model, page-3

Seems like a positive announcement.

Quote:
"AdAlta conducted a study of AD-214 administered intravenously at various doses and
dose intervals in the bleomycin mouse model. Treatment with AD-214 at 1-30mg/kg every
second day and 10-30mg/kg every fourth day resulted in a statistically significant reduction
in the Ashcroft Score of bleomycin-treated mice compared with mice receiving bleomycin
alone (Figure 1). In contrast, treatment with two drugs currently approved for IPF –
pirfenidone and nintedanib – did not result in a statistically significant reduction in Ashcroft
score under test conditions."

Looks like we have a clear winner here. Bring on the human trials.